uniQure N.V. (QURE)
| Previous close | 18.86 |
| Open | 18.62 |
| Bid | 18.04 x 2200 |
| Ask | 18.03 x 1300 |
| Day's range | 17.91 - 18.66 |
| 52-week range | 12.52 - 36.55 |
| Volume | |
| Avg. volume | 688,274 |
| Market cap | 840.636M |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.81 |
| Earnings date | 24 Oct 2022 - 28 Oct 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 52.19 |
- GlobeNewswire
uniQure to Participate in Upcoming Industry Conferences in September
LEXINGTON, Mass. and AMSTERDAM, Sept. 06, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Citi’s 17th Annual BioPharma Conference, September 7 – 8, 2022 Members of uniQure’s management team, including Matt Kapusta, chief executive officer, and Ricardo Dolmetsch, Ph.D., president of research
- Simply Wall St.
These Analysts Just Made A Neat Downgrade To Their uniQure N.V. (NASDAQ:QURE) EPS Forecasts
The latest analyst coverage could presage a bad day for uniQure N.V. ( NASDAQ:QURE ), with the analysts making...
- Motley Fool
Why uniQure Stock Is Crashing Today
Shares of uniQure N.V. (NASDAQ: QURE) are crashing today, down by 32.6% as of 11:19 a.m. ET. The steep decline came after the gene therapy specialist provided its second-quarter update Monday morning. Investors weren't all that interested in uniQure's financial results.
